Introduction {#s1}
============

Carbamazepine (CBZ), lamotrigine (LTG), oxcarbazepine (OXC), phenytoin (PHT), and phenobarbital (PB) share a similar aromatic structure and are widely used antiepileptic drugs (AEDs) to control seizures, trigeminal neuralgia, etc. However, they frequently lead to cutaneous adverse reactions (cADRs) ([@B1], [@B2]). cADRs comprise 10--30% of all reported adverse drug reaction ([@B3]--[@B5]), which vary from mild maculopapular eruption (MPE), hypersensitivity syndrome (HSS), to Stevens-Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN) ([@B6]). The most severe phenotypes SJS and TEN show high morbidity and mortality ([@B7]). It has been reported that 3.61% of patients treated with AEDs experience a skin rash induced by single AED, while 0.48% of patients show cross-reactivity sequentially induced by two or more AEDs (AEDs-induced cross-reactivity) in Han Chinese people, including aromatic and non-aromatic AEDs such as valproic acid, levetiracetam, and topiramate ([@B8]). cADRs frequently result in drug withdrawal, which increases the risk of seizure worse and medical costs ([@B9], [@B10]).

Although the mechanism of AEDs-induced cADRs is unclear, numerous studies have suggested that the major histocompatibility complex (also known as human leukocyte antigen, HLA) is involved in cADRs ([@B9]). Several HLA alleles were found to be associated with cADRs caused by single drug. The HLA-B^\*^15:02 allele is a strong risk factor for CBZ-induced SJS in Han Chinese people ([@B11], [@B12]), HLA-A^\*^24:02 is a common risk factor for aromatic AEDs induced SJS in the Southern Han Chinese people ([@B13]), and HLA-A^\*^31:01 is associated with CBZ-induced cADRs in Japanese and Caucasian people ([@B14], [@B15]). However, the HLA-related genetic risk factors of AEDs-induced cross-reactivity are unclear.

Here, we performed a case-control study to investigate the relationship between AEDs-induced cross-reactivity and HLA alleles in a Southern Han Chinese population.

Materials and Methods {#s2}
=====================

Participants
------------

Individuals were enrolled in southern China from 2009 to 2017, and treated at the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou First People\'s Hospital, the First Affiliated Hospital of Jinan University, and Guangdong 999 Brain Hospital in Guangzhou. The study was approved by the hospital ethics committee. All participants or their parents provided written informed consent in accordance with the Declaration of Helsinki.

Cases with cross-reactivity were defined as sequential rashes in response to two or more AEDs in the same individual. For example, when a patient experienced a skin rash induced by CBZ, CBZ was discontinued, and 2 weeks later the patient was treated with LTG, then rashes appeared again. The diagnosis of AEDs-induced cross-reactivity was confirmed by a dermatologist based on the clinical and morphological characteristics of the patients\' skin. MPE was defined as skin eruptions without mucosal or systemic involvement. SJS and TEN were diagnosed according to Roujeau\'s diagnostic criteria. Hypersensitivity syndrome was defined as a fever, rash, eosinophilia, and systemic manifestation (e.g., hepatitis and nephritis).

Five-hundred healthy volunteers who have not taken AEDs were recruited as normal controls. To verify the significant allele, we further increased the sample size of normal controls from 500 to 5,270. All healthy volunteers were recruited from the Healthy Physical Examination Center in the Second Affiliated Hospital of Guangzhou Medical University, and had not taken AEDs. Because most of the patients had taken CBZ, we recruited another cohort comprising of individuals with CBZ-induced MPE and CBZ-tolerant to clarify whether AEDs-induced cross-reactivity and CBZ-induced MPE have the same risk HLA allele. The cases with CBZ-induced MPE and CBZ tolerant controls were recruited from the Second Affiliated Hospital of Guangzhou Medical University between 2007 and 2018. CBZ tolerant controls were participants with epilepsy who took CBZ for at least 3 months without evidence of cutaneous adverse reactions.

All cases and controls were Southern Han Chinese.

Sequence based high-resolution HLA-A/B/C/DRB1 genotyping was performed by Shanghai Tissue Bank Biotechnology Co., Ltd. (Shanghai, China).

Statistical Analysis
--------------------

We performed statistical analyses using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). Fisher\'s exact tests were used to assess the difference in the presence of HLA alleles between the case and control groups. Because CBZ and LTG were the most common culprit drugs, we conducted an independent *t*-test to compare the mean age, latency to cADRs, and initial and maximum dosages between one group of CBZ/LTG as the first culprit drug and the other group of CBZ/LTG as the second culprit drug. *P* \< 0.05 (two-sided) were considered significantly different. The corrected *P* (*P*c) values were estimated by Bonferroni\'s correction for multiple comparisons (*n* = 12, 16, and 14 for HLA-A, HLA -B, and HLA-C alleles, respectively).

Meta-Analysis
-------------

We performed meta-analyses on data obtained from other studies to investigate the relationship between HLA-B^\*^13:01 allele and cADRs induced by AEDs or/and non-AEDs. A complete search of online databases, including MEDLINE, EMBASE, Google Scholar, was conducted.

The following terms were used in our searches: "HLA-B^\*^13:01" or "human leukocyte antigen B^\*^13:01," "Stevens--Johnson syndrome" or "SJS," "toxic epidermal necrolysis" or "TEN," "cutaneous adverse drug reactions" or "cADRs," "maculopapular eruption" or "MPE," "Antiepileptic drugs" or "AEDs." The latest search was conducted on April1, 2018.

Criteria for the selection of studies were: (1) the report was of a case-control study on association between HLA-B^\*^13:01 and cADRs induced by AEDs or non-AEDs; (2) the genotyping method and ethnicity were provided; (3) the presence of HLA-B^\*^13:01 in the cases, either the population controls or tolerant controls was reported or could be obtained from the authors or other sources; (4) the most recent publication with the largest number of samples was selected when duplicate publications were identified. Exclusion criteria were: (1) reports were not of case-control studies; (2) repeated studies; (3) studies did not indicate the presence of HLA-B^\*^13:01 in the case group and control group; (4) abstracts and reviews; (5) non-human studies.

The following information were extracted: the first author of the study, publication year, ethnicity of the study population, presence of HLA-B^\*^13:01 allele among cADRs cases and controls, total number of cADRs cases and controls, and main results. The methodological quality was assessed according to the recommendations of the Cochrane Collaboration Handbook (<https://www.cochrane.de>).

Data managements and analyses were conducted using STATA (Version 10.1 Stata Corp LP, College Station, TX, USA). Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to verify the association between the HLA-B^\*^13:01 allele and drugs-induced cADRs. Begg\'s test was used to evaluate publication bias ([@B16]). Statistical heterogeneity among studies was assessed via the Q statistic and *I*2 tests ([@B17]). A *P* \< 0.1 and an *I*^2^-value \>50% were defined as evidence of statistical heterogeneity, under which the association was assessed using the random model. Analyses were also performed separately on studies using different types of control patients (e.g., drug-tolerant or normal controls) and different drugs induced cADRs.

Seven articles met the criteria. Data from 8 studies, including the present study, were used for meta-analysis. The data included the populations from Thailand and China.

Results {#s3}
=======

Characteristics of Patients
---------------------------

A total of 23 patients with AEDs-induced cross-reactivity and 500 healthy volunteers were recruited in this study. The demographic variables and clinical manifestations of cases are summarized in [Table 1](#T1){ref-type="table"}. There were 14 females and 9 males. The average age was 24 years (range 6--53 years). All cases occurred as sequential rashes induced by two of the following drugs: CBZ, LTG, OXC, levetiracetam, topiramate, valproic acid, PB, and PHT. The phenotype of AED-induced cross-reactivity in this cohort was MPE without mucosal or systemic involvement.

###### 

Demographic and clinical characteristics of AEDs-induced cross-reactivity.

  **Number**   **Sex**   **Age[^**a**^](#TN1){ref-type="table-fn"}**   **First culprit drug**   **Second culprit drug**                                    
  ------------ --------- --------------------------------------------- ------------------------ ------------------------- ------- ------ ----- ---- ------ ------
  CR1          F         53                                            CBZ                      15                        300     600    LTG   9    12.5   12.5
  CR2          F         23                                            CBZ                      7                         300     500    LTG   13   12.5   25
  CR3          M         30                                            CBZ                      32                        500     500    OXC   7    25     25
  CR4          F         43                                            CBZ                      5                         200     200    OXC   6    150    300
  CR5          F         24                                            CBZ                      9                         200     400    OXC   16   150    450
  CR6          M         34                                            CBZ                      13                        200     600    OXC   18   150    450
  CR7          F         29                                            CBZ                      17                        200     600    OXC   17   150    450
  CR8          M         17                                            CBZ                      6                         200     200    TPM   21   50     100
  CR9          F         7                                             LTG                      2                         25      25     CBZ   14   200    400
  CR10         F         39                                            LTG                      9                         25      50     CBZ   13   600    600
  CR11         M         24                                            LTG                      11                        12.5    25     CBZ   15   200    400
  CR12         M         29                                            LTG                      15                        12.5    25     CBZ   16   200    500
  CR13         M         6                                             LTG                      16                        12.5    25     CBZ   8    200    200
  CR14         F         20                                            LTG                      7                         25      25     OXC   5    300    600
  CR15         F         16                                            LTG                      7                         12.5    25     OXC   7    300    300
  CR16         F         27                                            LTG                      9                         25      25     LEV   8    500    500
  CR17         F         7                                             LTG                      20                        3.125   12.5   VPA   10   250    250
  CR18         M         18                                            LTG                      9                         12.5    25     TPM   50   50     50
  CR19         M         20                                            PHT                      12                        100     200    LTG   9    25     25
  CR20         F         37                                            PHT                      16                        100     300    OXC   13   300    600
  CR21         M         28                                            OXC                      7                         300     300    LTG   7    100    100
  CR22         F         33                                            VPA                      21                        500     500    LTG   16   25     50
  CR23         F         7                                             PB                       13                        50      100    CBZ   7    200    300

*Age at development of cross-sensitivity*.

*F, female; M, male; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; TPM, topiramate; VPA, sodium valproate*.

CBZ and LTG were the most common culprit drugs. With respect to the sex ratio, mean age, latency to cADRs, and initial and maximum dosages, no significant difference was found between one group of CBZ/LTG as the first culprit drug and the other group of CBZ/LTG as the second culprit drug.

HLA-B^\*^13:01 Is Associated With Antiepileptic Drugs-Induced Cross-Reactivity
------------------------------------------------------------------------------

The HLA genotypes of patients with AEDs-induced cross-reactivity are shown in [Table 2](#T2){ref-type="table"}. The distribution of HLA alleles in the 23 cases and 500 normal controls is shown in [Table 3](#T3){ref-type="table"}. Three alleles were significantly associated with AEDs-induced cross-reactivity. The HLA-B^\*^13:01 allele was found in 8 (34.78%) of the 23 AEDs-induced cross-reactivity patients and 73 (14.60%) of the 500 normal controls (*P* = 0.02; OR: 3.12; 95% CI: 1.28--7.62; *Pc* = 0.32, *n* = 16 for HLA-B^\*^13:01 correction). The HLA-A^\*^11:02 allele was found in two (8.70%) of the 23 AEDs-induced cross-reactivity patients, and in none (0%) of the 500 normal controls (*P* = 0.002; OR: 68.32; 95% CI: 6.83--683.53; *Pc* = 0.02, n = 12 for HLA-A^\*^11:02 correction). The HLA-C^\*^04:03 allele was found in three (13.64%) of the 22 AED-induced cross-reactivity patients and 10 (2.01%) of the 498 normal controls (*P* = 0.01; OR: 7.71; 95% CI: 1.96-30.3; *Pc* = 0.14, *n* = 14 for HLA-C^\*^04:03 correction). Furthermore, one case with HLA-A^\*^11:02 and one case with HLA-C^\*^04:03 were positive for HLA-B^\*^13:01. If excluding these cases, the presence of HLA-A^\*^11:02 and C^\*^04:03 in the patients was 4.35% (1/23) and 9.09% (2/22), respectively. The presence of the two alleles HLA-A^\*^11:02 and C^\*^04:03 is very low in the normal Chinese population (<http://www.allelefrequencies.net>, such as 0 and 2.01% in this cohort). These results suggested HLA-B^\*^13:01 should be considered further. To exclude the possibility of lost significance, we compared the presence of HLA-B^\*^13:01 between the 23 patients of AEDs-induced cross-reactivity and a larger control cohort containing 5,270 normal individuals, which revealed a significant association between HLA-B^\*^13:01 and AEDs-induced cross-reactivity (8/23, 34.78%, vs. 763/5,270, 14.48%; *P* = 0.014, OR:3.15, 95%CI: 1.33--7.46).

###### 

Genotypes in the 23 patients with AEDs-induced cross-reactivity.

  **Number**   **HLA-A**         **HLA-B**         **HLA-C**         **HLA-DRB1**   **Culprit drug**
  ------------ ----------------- ----------------- ----------------- -------------- ------------------
  CR1          02:01/33:03       **13:01**/38:02   03:04/07:02       08:03/09:01    CBZ/LTG
  CR2          02:03/11:01       **13:01/13:01**   03:04/03:04       12:02/16:02    CBZ/LTG
  CR3          11:01/11:01       15:02/15:18       02:02/08:01       04:04/15:01    CBZ/OXC
  CR4          11:01/31:01       15:01/56:04       01:02/03:03       14:54/15:02    CBZ/OXC
  CR5          11:01/11:01       **13:01**/35:01   03:03/03:04       09:01/15:01    CBZ/OXC
  CR6          02:07/02:07       46:01/46:01       01:02/01:02       09:01/09:01    CBZ/OXC
  CR7          02:01/11:01       15:25/39:01       **04:03**/07:02   09:01/16:02    CBZ/OXC
  CR8          11:01/**11:02**   **13:01**/58:01   03:02/03:04       03:01/15:01    CBZ/TPM
  CR9          11:01/24:02       40:01/40:01       03:04/07:02       08:03/14:54    LTG/CBZ
  CR10         24:02/24:02       39:01/48:01       07:02/15:02       12:02/15:01    LTG/CBZ
  CR11         11:01/02:07       15:02/46:01       01:02/08:01       09:01/09:01    LTG/CBZ
  CR12         11:01/74:02       **13:01**/51:01   08:01/14:02       03:01/14:04    LTG/CBZ
  CR13         11:01/11:01       40:01/40:01       None              None           LTG/CBZ
  CR14         02:01/33:03       40:01/58:01       03:02/15:02       03:01/11:01    LTG/OXC
  CR15         02:03/11:01       40:01/40:01       **04:03**/07:66   12:02/15:01    LTG/OXC
  CR16         02:03/**11:02**   40:01/40:01       07:02/07:02       15:01/15:02    LTG/LEV
  CR17         02:03/24:02       35:01/40:01       03:04/04:01       09:01/14:05    LTG/VPA
  CR18         30:01/30:01       13:02/13:02       06:02/06:02       07:01/07:01    LTG/TPM
  CR19         02:03/02:07       46:01/38:02       01:02/07:02       04:05/16:02    PTH/LTG
  CR20         02:07/23:01       45:01/46:01       01:02/06:02       07:01/08:03    PHT/OXC
  CR21         02:07/02:07       **13:01**/46:01   01:02/03:04       07:01/15:01    OXC/LTG
  CR22         11:01/11:01       **13:01**/15:25   03:04/**04:03**   12:02/12:02    VPA/LTG
  CR23         02:01/24:20       **13:01**/40:01   03:02/07:02       12:02/15:01    PB/CBZ

*AEDs, antiepileptic drugs*.

*Bold black indicates those alleles are significant*.

*None: individual was not subjected to HLA genotyping because of insufficient DNA*.

*^\*^ Individual was positive for HLA-B^\*^13:01 and HLA-A^\*^11:02, or positive for HLA-B^\*^13:01 and HLA-C^\*^04:03*.

###### 

Association between HLA alleles and AEDs-induced cross-reactivity.

                                                **No. of HLA genotypes / Total no. (%)**   **Cases vs. Normal Controls**                                               
  --------------------------------------------- ------------------------------------------ ------------------------------- ------------------------------------------- -----------------------
  A[^\*^](#TN3){ref-type="table-fn"}02:01       4/23 (17.39)                               74/500 (14.8)                   0.97                                        1.21 (0.40--3.66)
  A[^\*^](#TN3){ref-type="table-fn"}02:03       5/23 (21.74)                               44/500 (8.80)                   0.09                                        2.88 (1.02--8.13)
  A[^\*^](#TN3){ref-type="table-fn"}02:07       5/23 (21.74)                               117/500 (23.40)                 0.85                                        0.91 (0.33--2.50)
  A[^\*^](#TN3){ref-type="table-fn"}11:01       12/23 (52.17)                              252/500 (50.40)                 0.87                                        1.07 (0.47--2.48)
  A[^\*^](#TN3){ref-type="table-fn"}11:02       2/23 (8.70)                                0/500 (0.00)                    0.002[^\*^](#TN3){ref-type="table-fn"}      68.32 (6.83--683.53)
  A[^\*^](#TN3){ref-type="table-fn"}23:01       1/23 (4.35)                                1/500 (0.20)                    0.09                                        22.68 (1.37--374.68)
  A[^\*^](#TN3){ref-type="table-fn"}24:02       3/23 (13.04)                               148/500 (29.60)                 0.09                                        0.36 (0.10--1.22)
  A[^\*^](#TN3){ref-type="table-fn"}24:20       1/23 (4.35)                                3/500 (0.60)                    0.17                                        7.53 (0.75--75.34)
  A[^\*^](#TN3){ref-type="table-fn"}30:01       1/23 (4.35)                                24/500 (4.80)                   1.00                                        0.90 (0.12--6.97)
  A[^\*^](#TN3){ref-type="table-fn"}31:01       1/23 (4.35)                                21/500 (4.20)                   1.00                                        1.04 (0.13--8.06)
  A[^\*^](#TN3){ref-type="table-fn"}33:03       2/23 (8.70)                                59/500 (11.80)                  0.90                                        0.71 (0.16--3.11)
  A[^\*^](#TN3){ref-type="table-fn"}74:02       1/23 (4.35)                                0/500 (0.00)                    0.04                                        43.57 (3.81--498.11)
  **B[^\*^](#TN3){ref-type="table-fn"}13:01**   **8/23 (34.78)**                           **73/500 (14.60)**              **0.02[^\*^](#TN3){ref-type="table-fn"}**   **3.12 (1.28--7.62)**
  B[^\*^](#TN3){ref-type="table-fn"}13:02       1/23 (4.35)                                29/500 (5.80)                   1.00                                        0.74 (0.10--5.67)
  B[^\*^](#TN3){ref-type="table-fn"}15:01       1/23 (4.35)                                35/500 (7.00)                   0.94                                        0.60 (0.08--4.61)
  B[^\*^](#TN3){ref-type="table-fn"}15:02       2/23 (8.70)                                64/500 (12.80)                  0.80                                        0.65 (0.15--2.83)
  B[^\*^](#TN3){ref-type="table-fn"}15:18       1/23 (4.35)                                5/500 (1.00)                    0.24                                        4.50 (0.50--40.17)
  B[^\*^](#TN3){ref-type="table-fn"}15:25       2/23 (8.70)                                12/500 (2.40)                   0.12                                        3.87 (0.81--18.42)
  B[^\*^](#TN3){ref-type="table-fn"}35:01       2/23 (8.70)                                25/500 (5.00)                   0.76                                        1.81 (0.40--8.15)
  B[^\*^](#TN3){ref-type="table-fn"}38:02       2/23 (8.70)                                33/500 (6.60)                   1.00                                        1.35 (0.30--6.00)
  B[^\*^](#TN3){ref-type="table-fn"}39:01       2/23 (8.70)                                18/500 (3.60)                   0.22                                        2.55 (0.56--11.72)
  B[^\*^](#TN3){ref-type="table-fn"}40:01       7/23 (30.43)                               178/500 (35.60)                 0.61                                        0.79 (0.32--1.96)
  B[^\*^](#TN3){ref-type="table-fn"}45:01       1/23 (4.35)                                2/500 (0.40)                    0.13                                        11.32 (0.99--129.61)
  B[^\*^](#TN3){ref-type="table-fn"}46:01       5/23 (21.74)                               136/500 (27.20)                 0.56                                        0.74 (0.27--2.04)
  B[^\*^](#TN3){ref-type="table-fn"}48:01       1/23 (4.35)                                7/500 (1.40)                    0.30                                        3.20 (0.38--27.17)
  B[^\*^](#TN3){ref-type="table-fn"}51:01       1/23 (4.35)                                38/500 (7.60)                   0.86                                        0.55 (0.07--4.21)
  B[^\*^](#TN3){ref-type="table-fn"}56:04       1/23 (4.35)                                1/500 (0.20)                    0.09                                        22.68 (1.37--374.68)
  B[^\*^](#TN3){ref-type="table-fn"}58:01       1/23 (4.35)                                51/500 (10.20)                  0.58                                        0.40 (0.05--3.03)
  C[^\*^](#TN3){ref-type="table-fn"}01:02       6/22 (27.27)                               166/498 (33.33)                 0.55                                        0.75 (0.29--1.95)
  C[^\*^](#TN3){ref-type="table-fn"}02:02       1/22 (4.55)                                0/498 (0.00)                    0.04                                        45.36 (3.96--519.49)
  C[^\*^](#TN3){ref-type="table-fn"}03:02       3/22 (13.64)                               86/498 (17.27)                  0.88                                        0.76 (0.22--2.61)
  C[^\*^](#TN3){ref-type="table-fn"}03:03       2/22 (9.09)                                50/498 (10.04)                  1.00                                        0.90 (0.20--3.95)
  C[^\*^](#TN3){ref-type="table-fn"}03:04       8/22 (36.36)                               110/498 (22.09)                 0.19                                        2.02 (0.82--4.93)
  C[^\*^](#TN3){ref-type="table-fn"}04:01       1/22 (4.55)                                20/498 (0.42)                   0.60                                        1.14 (0.15--8.89)
  C[^\*^](#TN3){ref-type="table-fn"}04:03       3/22 (13.64)                               10/498 (2.01)                   0.01[^\*^](#TN3){ref-type="table-fn"}       7.71 (1.96--30.30)
  C[^\*^](#TN3){ref-type="table-fn"}06:02       2/22 (9.09)                                40/498 (8.03)                   1.00                                        1.15 (0.26--5.08)
  C[^\*^](#TN3){ref-type="table-fn"}07:02       7/22 (31.82)                               156/498 (31.33)                 0.96                                        1.02 (0.41--2.56)
  C[^\*^](#TN3){ref-type="table-fn"}07:66       1/22 (4.55)                                0/498 (0.00)                    0.04                                        45.36 (3.96--519.49)
  C[^\*^](#TN3){ref-type="table-fn"}08:01       3/22 (13.64)                               102/498 (20.48)                 0.61                                        0.61 (0.18--2.11)
  C[^\*^](#TN3){ref-type="table-fn"}14:02       1/22 (4.55)                                38/498 (7.63)                   0.90                                        0.58 (0.08--4.40)
  C[^\*^](#TN3){ref-type="table-fn"}15:02       2/22 (9.09)                                26/498 (5.22)                   0.76                                        1.82 (0.40--8.19)
  DRB1[^\*^](#TN3){ref-type="table-fn"}03:01    3/22 (13.64)                               39/500 (7.80)                   0.56                                        1.87 (0.53--6.59)
  DRB1[^\*^](#TN3){ref-type="table-fn"}04:04    1/22 (4.55)                                5/500 (1.00)                    0.23                                        4.71 (0.53--42.17)
  DRB1[^\*^](#TN3){ref-type="table-fn"}04:05    1/22 (4.55)                                38/500 (7.60)                   0.91                                        0.58 (0.08--4.42)
  DRB1[^\*^](#TN3){ref-type="table-fn"}07:01    3/22 (13.64)                               43/500 (8.60)                   0.67                                        1.68 (0.48--5.90)
  DRB1[^\*^](#TN3){ref-type="table-fn"}08:03    3/22 (13.64)                               101/500 (20.20)                 0.63                                        0.62 (0.18--2.15)
  DRB1[^\*^](#TN3){ref-type="table-fn"}09:01    6/22 (27.27)                               175/500 (35.00)                 0.46                                        0.70 (0.27--1.81)
  DRB1[^\*^](#TN3){ref-type="table-fn"}11:01    1/22 (4.55)                                59/500 (11.80)                  0.48                                        0.36 (0.05--2.70)
  DRB1[^\*^](#TN3){ref-type="table-fn"}12:02    5/22 (22.73)                               100/500 (20.00)                 0.97                                        1.18 (0.42--3.27)
  DRB1[^\*^](#TN3){ref-type="table-fn"}14:04    1/22 (4.55)                                4/500 (0.80)                    0.19                                        5.91 (0.63--55.16)
  DRB1[^\*^](#TN3){ref-type="table-fn"}14:05    1/22 (4.55)                                17/500 (3.40)                   0.55                                        1.35 (0.17--10.65)
  DRB1[^\*^](#TN3){ref-type="table-fn"}14:54    2/22 (9.09)                                40/500 (8.00)                   1.00                                        1.15 (0.26--5.10)
  DRB1[^\*^](#TN3){ref-type="table-fn"}15:01    8/22 (36.36)                               119/500 (23.80)                 0.18                                        1.83 (0.75--4.47)
  DRB1[^\*^](#TN3){ref-type="table-fn"}15:02    2/22 (9.09)                                21/500 (4.20)                   0.25                                        2.28 (0.50--10.41)
  DRB1[^\*^](#TN3){ref-type="table-fn"}16:02    3/22 (13.64)                               44/500 (8.80)                   0.69                                        1.64 (0.47--5.75)

*AEDs, antiepileptic drugs; CBZ, carbamazepine; CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio*.

*Bold values indicates the allele is an important genotype*.

*Several individuals were not subjected to HLA genotyping because of insufficient DNA*.

*P-value is significant and unadjusted*.

Since 18 subjects (18/23, 78.26%) showed cross-reactivity induced by two aromatic AEDs, we compared the presence of HLA-B^\*^13:01 between the 18 patients of aromatic AEDs-induced cross-reactivity (6/18, 33.33%) and the two normal control cohorts, which showed no significant difference (6/18 vs. 73/500, *P* = 0.066; 6/18 vs. 763/5,270, *P* = 0.054, respectively).

Because most of the AEDs-induced cross-reactivity patients (14/23, 60.9%) had taken CBZ, we recruited another cohort comprising of individuals with CBZ-induced MPE (145) and CBZ-tolerant controls (179) to clarify whether AEDs-induced cross-reactivity and CBZ-induced MPE have the same risk HLA allele. The HLA-B^\*^13:01 presence was significantly higher in AEDs-induced cross-reactivity individuals than in CBZ-tolerant individuals (8/23, 34.78%, vs. 28/179, 15.64%; *P* = 0.049, OR: 2.88, 95%CI: 1.11--7.42), while its presence in CBZ-induced MPE was numerically higher than that in CBZ-tolerant individuals without statistical significance (33/145, 22.76%, vs. 28/179, 15.64%; *P* = 0.103) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

In addition, in this cohort, two of 23 AEDs-induced cross-reactivity patients (2/23) were positive for HLA-B^\*^15:02, three of 23 patients (3/23) were positive for HLA-A^\*^24:02, and one patient (1/23) was positive for HLA-A^\*^31:01. Compared to the normal controls, there was no significant difference in the presence of HLA-B^\*^15:02, HLA-A^\*^24:02, or HLA-A^\*^31:01 (8.7% vs. 12.80%, *P* = 0.80; 13.04% vs. 29.60%, *P* = 0.09; 4.35% vs. 4.20%, *P* = 1.0, respectively) ([Table 3](#T3){ref-type="table"}).

Meta-Analysis: HLA-B^\*^13:01 and cADRs
---------------------------------------

To clarify the relationship between HLA-B^\*^13:01 and cADRs, a meta-analysis was performed using data from different populations. Seven case-control studies including Thailand and China population met the criteria ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}). The meta-analysis analyzed 8 studies, including the present study. The data covered two aspects, i.e., HLA-B^\*^13:01 is associated with cADRs induced by single AED, and HLA-B^\*^13:01 is associated with cADRs induced by single non-AED. There was a total of 254 cases with cADRs induced by single AED, 446 AEDs tolerant controls, and 6,678 normal controls, and there was a significant association between HLA-B^\*^13:01 and cADRs induced by single AED (*P* = 0.000), compared to tolerant controls and normal controls ([Figure 1A](#F1){ref-type="fig"}). There was a total of 117 cases with cADRs induced by single non-AED, 1,195 non-AEDs tolerant controls, and 3,309 normal controls, and there was a significant association between HLA-B^\*^13:01 and cADRs induced by single non-AED (*P* = 0.000), compared to tolerant controls and normal controls ([Figure 1B](#F1){ref-type="fig"}). We further combined the cases of cADRs induced by AEDs with the case of cADRs induced by non-AEDs, and there was a significant association between HLA-B^\*^13:01 and cADRs in Thai and Chinese populations (*P* = 0.000), compared to tolerant controls and normal controls ([Figure 1C](#F1){ref-type="fig"}).

![Distribution of HLA-B^\*^13:01 allele in cutaneous adverse reactions induced by AEDs and non-AEDs. **(A)** Presence of the HLA-B^\*^ 13:01 allele in one AEDs-induced cADRs and controls. **(B)** Presence of the HLA-B^\*^ 13:01 allele in non-AEDs induced cADRs and controls. **(C)** Presence of the HLA-B^\*^ 13:01 allele in drugs (AEDs and non-AEDs) induced cADRs and controls.](fneur-10-00614-g0001){#F1}

Discussion {#s4}
==========

In the present study, we found that the HLA-B^\*^13:01 allele was significantly associated with AEDs-induced cross-reactivity with a sensitivity of 34.78% and specificity of 85.40%. If Bonferroni\'s correction was performed for multiple comparisons, the significance of HLA-B^\*^13:01 would be lost \[*Pc* = 0.32 (16 × 0.02)\]. Considering the HLA-B was an independent variable, while the frequency of each allele was not. To exclude the possibility of lost significance, we compared the presence of HLA-B^\*^13:01 between the 23 patients with AEDs-induced cross-reactivity and a larger control cohort containing 5,270 normal individuals. A significant difference was found between the two groups, suggesting a significant association between HLA-B^\*^13:01 and AEDs-induced cross-reactivity. Considering most of the patients (14/23, 60.9%) had taken CBZ, we recruited another cohort comprised of individuals with CBZ-induced MPE (145) and CBZ-tolerant (179) to clarify whether AEDs-induced cross-reactivity and CBZ-induced MPE have the same risk HLA allele. We found that HLA-B^\*^13:01 presence was significantly higher in AEDs-induced cross-reactivity individuals than in CBZ-tolerant individuals, while its presence in CBZ-induced MPE was numerically higher than that in CBZ-tolerant control without reaching statistical significance. These results suggest that HLA-B^\*^13:01 is a relatively higher risk factor for AEDs-induced cross-reactivity.

Previous studies demonstrated that HLA-B^\*^13:01 is associated with PHT-SJS/TEN in Han Chinese people, and with severe cADRs induced by PHT or PB in Thai people ([@B18]--[@B21]). Meta-analysis of data from independent studies including studies conducted in Thailand and China revealed that HLA-B^\*^13:01 may be a potential risk factor for cADRs induced by AEDs ([Figure 1A](#F1){ref-type="fig"}). Additionally, the association with cADRs was not limited to AEDs, and studies reported that HLA-B^\*^13:01 was associated with cADRs induced by dapsone and salazosulfapyridine ([@B22]--[@B26]). Thus, we conducted a meta-analysis to confirm that HLA-B^\*^13:01 was associated with cADRs induced by non-AEDs in Chinese and Thai populations ([Figure 1B](#F1){ref-type="fig"}). We further demonstrated that HLA-B^\*^13:01 was associated with cADRs induced by drugs including AEDs and non-AEDs ([Figure 1C](#F1){ref-type="fig"}). The HLA-B^\*^13:01 allele is present as a medium common allele in Asian populations (<https://www.allelefrequencies.net>). Based on these data, HLA-B^\*^13:01 may be a common genetic marker for predicting cADRs in Asian populations.

cADRs were considered as idiosyncratic immune responses involving the T cell-mediated drug hypersensitivities. At present, the mechanism underlying the HLA involved in AEDs-induced cADRs was unclear, and even for AEDs-induced cross-sensitivity. Previous studies demonstrated that abacavir can bind within the F pocket of the peptide-binding groove of HLA-B^\*^57:01 and then alter the repertoire of self-peptides presented to T cells, resulted in abacavir-induced cADRs ([@B27], [@B28]). Specific T-cell receptor is crucial for CBZ-induced SJS in individuals with HLA-B^\*^15:02 ([@B29]). Symptoms are relieved upon cessation of culprit drug administration, which is consistent with removal of the antigen; however, reintroduction of the drug or a drug with a similar structure can induce an allergic reaction, presumably by rapidly activating memory T cells ([@B30]--[@B32]). Several studies demonstrated that certain HLAgenotypes can induce T-cell activation in response to a specific drug, resulting in an immune response. The function of the classical HLA molecules is to present the drug for immune surveillance, followed by activation and clonal expansion of CD8^+^T or CD4^+^T cells to trigger immunological responses ([@B33]). Activated CD8^+^T or CD4^+^T cells have been detected in the epidermis and dermis of patients with cADRs ([@B34]). Further studies are required to explore the mechanism of HLA-B^\*^13:01 involvement in AEDs-induced cross-sensitivity.

Additionally, HLA-A^\*^11:02 and HLA-C^\*^04:03 showed significant association with AEDs-induced cross reactivity. However, one of two cases carrying HLA-A^\*^11:02 was positive for HLA-B^\*^13:01 and one of three cases carrying HLA-C^\*^04:03 was positive for HLA-B^\*^13:01. After excluding cases that were also positive for the HLA-B^\*^13:01, there was only one patient positive for HLA-A^\*^11:02 and two patients positive for HLA-C^\*^04:03. HLA-A^\*^11:02 and HLA-C^\*^04:03 are rare alleles and their frequency were low to 0% in Han Chinese populations (<https://www.allelefrequencies.net>). Hence, the relationship between HLA-A^\*^11:02 or HLA-C^\*^04:03 and AEDs-induced cross-reactivity requires further analysis.

Previous studies demonstrated that HLA-B^\*^15:02 is specifically associated with CBZ-induced SJS/TEN, HLA-A^\*^24:02 is commonly associated with AEDs-induced SJS/TEN in the Han Chinese ([@B13], [@B35]), HLA-A^\*^24:02 may be associated with the cross-reactivity of DRESS/MPE induced by PHT and LTG, and HLA-B^\*^38:01 may be a major responsible allele for the cross-reactivity of SJS/TEN induced by PHT and LTG in Spanish people ([@B36]). However, we failed to find that these alleles were associated with AEDs-induced cross reactivity, the phenotype of the cross-reactivity in this cohort was MPE, which may explain this result. Additionally, a previous study reported an association between the specific haplotype HLA-A^\*^02:01/-B^\*^35:01/-C^\*^04:01 and LTG-induced MPE in Mexican Mestizo people ([@B37]), indicating that further studies should explore the relationship between the specific HLA haplotype and cross-reactivity induced by AEDs.

The rate of cross-reactivity caused by two aromatic AEDs was higher than that caused by one aromatic drug and one non-aromatic drug. It was reported that cross-sensitivity induced by aromatic AEDs (CBZ, LTG, OXC, PHT, and PB) occurred in 40--58% of patients because of their similar chemical structures and intermediary metabolism molecules ([@B38]). If detoxification of this toxic metabolite is insufficient, it may bind to cellular macromolecules, causing cell necrosis or a secondary immunological response. Among the aromatic drugs, CBZ and OXC, as well as LTG and CBZ, were administered more frequently than the other drugs. Thus, clinicians should use caution when determining replacement drug-therapy among aromatic AEDs; particularly, replace CBZ with OXC, and LTG with CBZ.

We found no significant difference in terms of the sex ratio, mean age, latency to cADRs, and initial and maximum dosages between CBZ/LTG as the first culprit drug and CBZ/LTG as the second culprit drug. Because of the different chemical and pharmacological properties of the causative drug, and heterogeneity of the clinical presentations, it is not surprising that idiosyncratic reactions involve a broad range of mechanism, and that more than one risk alleles may be involved in any single event.

Further Improvement
-------------------

This study had several limitations. First, we did not divide the cases into subgroups according to cross-reactivity induced by the same order of drug prescribed due to the limit sample. Second, we did not exactly match the drug tolerant subgroup. To decrease deviation, we investigated the significance of the association by comparison with a large number of normal individuals. A further study with a larger samples size and cases from multiple centers along with exactly matched tolerant controls should be conducted to confirm that the HLA-B^\*^13:01 allele is a risk factor for AEDs-induced cross-reactivity, and a common risk factor for cADRs.

Conclusion {#s5}
==========

The HLA-B^\*^13:01 allele is potentially associated with AED-cADRs in general, possibly with stronger effect in cross-reactivity. Our finding suggests that screening for HLA-B^\*^13:01 prior to starting AEDs therapy may help to avoid AEDs-induced cross-reactivity. HLA-A^\*^31:01 testing can alert clinicians patients to patients who are at an increased risk of AEDs-induced cross-reactivity, and patients who have already experienced cADRs can be advised to avoid structurally related drugs.
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CBZ

:   carbamazepine

LTG

:   lamotrigine

OXC

:   oxcarbazepine

PHT

:   phenytoin

PB

:   phenobarbital

AED

:   antiepileptic drug

cADRs

:   cutaneous adverse reactions

MPE

:   maculopapular exanthema

HSS

:   hypersensitivity syndrome

SJS

:   Stevens-Johnson syndrome

TEN

:   toxic epidermal necrolysis

VPA

:   valproic acid

LEV

:   levetiracetam

TPM

:   topiramate

HLA

:   human leukocyte antigen.
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